Stock AURA AURA BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Aura Biosciences, Inc.

Equities

AURA

US05153U1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
7.51 USD +0.54% Intraday chart for Aura Biosciences, Inc. +2.18% -15.24%
May. 29 Transcript : Aura Biosciences, Inc. - Special Call
May. 09 Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aura Biosciences : Corporate Presentation June 2024
PU
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
AQ
Transcript : Aura Biosciences, Inc. - Special Call
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
AQ
Aura Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
AQ
Aura Biosciences to Participate in Upcoming Investor Conferences
AQ
Raj Parekh to Resign as Member of the Board of Directors of Aura Biosciences, Inc., Effective June 20, 2024
CI
Aura Biosciences Shares Rise Following Q4 Results
MT
Aura Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
BU
Aura Biosciences to Participate in Upcoming Investor Conferences
BU
BTIG Cuts Aura Biosciences' Price Target to $21 From $38, Keeps Buy Rating
MT
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan for First-Line Treatment of Early-Stage Choroidal Melanoma
AQ
Arix Bioscience's Portfolio Company Doses First Patient in Late-stage Trial of Choroidal Melanoma Therapy
MT
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
BU
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
CI
North American Morning Briefing : Stock Futures Hold Near Two-Month Highs
DJ
Aura Biosciences Insider Bought Shares Worth $1,434,987, According to a Recent SEC Filing
MT
Aura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AURA Stock
  4. News Aura Biosciences, Inc.